Author(s) Details:
Abdullah M. Nasrat
Zaitona Medical Center, Medina, Saudi Arabia.
Rania Ashour
Al Hayat National Hospital, Medina, Saudi Arabia.
This section is a part of the chapter: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations
Lung cancer is the leading cause of cancer deaths worldwide. Lung cancer causes more deaths than blood, colorectal, prostate, and brain cancers combined. In 2021, an estimated 235,760 new cases of lung cancer were diagnosed in the United States. The number of deaths was estimated at over 131,880. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for more than two-thirds of cases. Most patients (84%) have advanced disease at the time of diagnosis. Identification of genetic changes that can be driver mutations: EGFR, ALK, PI3K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS1 guides appropriate treatment. The approval and adoption of therapeutic providers that target these genetic alterations has led to a 35% decrease in mortality among men with NSCLC diagnosed in 2001 to 26% in 2014. “Similar rates have been found among women with NSCLC.
How to Cite
Nasrat, A. M., Nasrat, S. A., Nasrat, R. M., Nasrat, M. M., & Babiker, S. Y. (2025). Helicobacter pylori and Hyperuricemia: Revisiting Gout Diagnosis in Young Adults with Normal Renal Function. Medical Science: Trends and Innovations Vol. 4, 1–8. https://doi.org/10.9734/bpi/msti/v4/3641